{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:46:31Z","timestamp":1790779591976,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.radonc.2023.109697","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T14:14:22Z","timestamp":1683641662000},"page":"109697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy"],"prefix":"10.1016","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4776-115X","authenticated-orcid":false,"given":"Marion","family":"Tonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Campeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Filion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Beliveau-Nadeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Bahig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109697_b0005","unstructured":"Cancer (IARC) TIA for R on. Global Cancer Observatory [Internet]. [cited 2022 Jan 24]. Available from: https:\/\/gco.iarc.fr\/."},{"key":"10.1016\/j.radonc.2023.109697_b0010","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2023.109697_b0015","doi-asserted-by":"crossref","first-page":"v103","DOI":"10.1093\/annonc\/mdq207","article-title":"Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Crin\u00f2","year":"2010","journal-title":"Ann Oncol."},{"key":"10.1016\/j.radonc.2023.109697_b0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00066-018-1416-x","article-title":"ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: statement from the DEGRO\/DGMP working group stereotactic radiotherapy and radiosurgery","volume":"195","author":"Wilke","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.109697_b0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0030","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.radonc.2023.109697_b0035","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.02.010","article-title":"Stage-I small cell lung cancer: a new potential option for stereotactic ablative radiation therapy? A review of literature","volume":"112","author":"Alongi","year":"2017","journal-title":"Critical Rev Oncol\/Hematol"},{"key":"10.1016\/j.radonc.2023.109697_b0045","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0050","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0055","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ijrobp.2019.08.019","article-title":"One versus three fractions of stereotactic body radiation therapy for peripheral Stage I to II non-small cell lung cancer: a randomized, multi-institution, Phase 2 Trial","volume":"105","author":"Singh","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocpiqo.2017.11.001","article-title":"Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience","volume":"2","author":"Hobbs","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.radonc.2023.109697_b0070","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijrobp.2014.05.048","article-title":"Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT","volume":"90","author":"Hearn","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ijrobp.2014.07.030","article-title":"Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes","volume":"90","author":"McAvoy","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0080","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0085","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109697_b0090","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ijrobp.2013.06.2048","article-title":"Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability for treatment of early non-small cell lung cancer: a single-center experience","volume":"87","author":"Bahig","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0095","doi-asserted-by":"crossref","first-page":"667","DOI":"10.7785\/tcrt.2012.500445","article-title":"Excellent cancer outcomes following patient-adapted robotic lung SBRT But a case for caution in idiopathic pulmonary fibrosis","volume":"14","author":"Bahig","year":"2015","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2023.109697_b0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2019.01.035","article-title":"Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours","volume":"134","author":"Lenglet","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0105","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.ijrobp.2014.05.135","article-title":"Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer","volume":"90","author":"Timmerman","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.109697_b0115","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2023.109697_b0120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study","volume":"75","author":"Fakiris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2009.12.008","article-title":"Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications","volume":"94","author":"Chi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0130","first-page":"00658","article-title":"Ten-Year experience in implementing single-fraction lung SBRT for medically inoperable early-stage lung cancer","volume":"S0360\u20133016","author":"Videtic","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.radonc.2023.109697_b0135","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/j.prro.2019.12.003","article-title":"Stereotactic image guided lung radiation therapy for clinical early stage non-small cell lung cancer: a long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis","volume":"10","author":"Fernandez","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12094-015-1361-4","article-title":"Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients","volume":"18","author":"Ceniceros","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0145","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2013.08.020","article-title":"The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer","volume":"87","author":"Allibhai","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.prro.2018.04.004","article-title":"Local control for clinical stage I non-small cell lung cancer treated with 5-fraction stereotactic body radiation therapy is not associated with treatment schedule","volume":"8","author":"Samson","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jjco\/hyx179","article-title":"Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"48","author":"Ye","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0160","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/JTO.0b013e31822e71d8","article-title":"Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer","volume":"6","author":"Haasbeek","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0175","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cUltracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0180","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2015.09.028","article-title":"Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and long-term clinical outcomes","volume":"117","author":"Tekatli","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0185","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109697_b0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109697_b0195","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ijrobp.2014.01.022","article-title":"Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a \u201cNo Fly Zone\u201d","volume":"88","author":"Chang","year":"2014","journal-title":"Int J Radiation Oncol*Biology*Phys"},{"key":"10.1016\/j.radonc.2023.109697_b0200","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.radonc.2008.07.013","article-title":"Dose-individualized stereotactic body radiotherapy for T1\u20133N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy","volume":"88","author":"Chen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/tlcr.2018.08.16","article-title":"Combining stereotactic body radiation therapy with immunotherapy: current data and future directions","volume":"8","author":"Lin","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2023.109697_b0215","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.radonc.2019.08.010","article-title":"Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT","volume":"142","author":"Kennedy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109697_b0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/thx.2010.136747","article-title":"Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning","volume":"66","author":"Ashraf","year":"2011","journal-title":"Thorax"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:26:02Z","timestamp":1759123562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":42,"alternative-id":["S0167814023002359"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109697","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109697"}}